ArticleEuropean journal of clinical pharmacology2013
Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Article in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Pooled it
- The Impact of Genetic Variation on Drug Response in Adult IBD: A Systematic Review.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025Review
- Pharmacogenomic landscape of TNF inhibitors in the Middle Eastern Qatari population.Frontiers in immunology · 2025Article
- Functional evaluation of synbiotic combination ofCurrent research in food science · 2025Article
- Immune-mediated impairment of tonic immobility defensive behavior in an experimental model of colonic inflammation.Pflugers Archiv : European journal of physiology · 2024Article
- Engineering a Novel Probiotic Toolkit inACS synthetic biology · 2024Article
- Identification of Diagnosis and Typological Characteristics Associated with Ferroptosis for Ulcerative ColitisEndocrine, metabolic & immune disorders drug targets · 2024Article
- Evaluation of the Mechanism of Sinomenii Caulis in Treating Ulcerative Colitis based on Network Pharmacology and Molecular Docking.Current computer-aided drug design · 2024Article
- Article
- Cytokine and microbiota profiles in obesity-related hypertension patients.Frontiers in cellular and infection microbiology · 2023Article
- Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn's disease.Scientific reports · 2022Article
- Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn's Disease.Frontiers in immunology · 2022Article
- Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review.Biomedicines · 2021Review
- Cytokine Drizzle-The Rationale for Abandoning "Cytokine Storm".Shock (Augusta, Ga.) · 2021Review
- Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.Pharmaceutics · 2021Review
- Treatments of inflammatory bowel disease toward personalized medicine.Archives of pharmacal research · 2021Review
- Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.Journal of nanobiotechnology · 2020Article
- Serum Biomarkers for Inflammatory Bowel Disease.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimInflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are partially attributable to an increased secretion of proinflamatory cytokines, such as tumour necrosis factor (TNF) and interleukin-1β (IL1β), which play essential roles in the disease pathogenesis and are target molecules for specific therapy. Given the inter-individual variability in the response to the anti-TNF monoclonal antibody infliximab, the aim of our study was to explore the predictive value of TNF and/or IL1β as surrogate markers of infliximab response.
methodsSerial serum concentrations of TNF and IL1β and TNF promoter region and IL1B polymorphisms were determined in 47 patients (29 CD and 18 UC) receiving infliximab and correlated with treatment response.
resultsBaseline serum concentrations of TNF and IL1β were higher in UC patients than in CD patients (p = 0.0097 and 0.0024, respectively). CD patients showing <0.64 pg/ml IL1β at baseline were more frequently responders than non-responders (p = 0.036), and the C allele of the IL1B polymorphism was associated with higher IL1β serum concentrations (p = 0.026) and with poorer clinical remission after 14 weeks of infliximab treatment. No significant association was found between serum TNF concentration or TNF polymorphism and patient response to infliximab.
conclusionThis is the first study evaluating the pharmacogenetic role of the rs1143634 polymorphism of IL1B and TNF polymorphisms in infliximab-treated IBD patients. We found an association between the rs1143634 C allele and higher serum IL1β concentrations and a lower response to infliximab treatment in CD patients that warrants the interest of future studies in larger and independent series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.